Laminin compensation in collagen alpha3(IV) knockout (Alport) glomeruli contributes to permeability defects
- PMID: 17699809
- DOI: 10.1681/ASN.2007030328
Laminin compensation in collagen alpha3(IV) knockout (Alport) glomeruli contributes to permeability defects
Abstract
Alport disease is caused by mutations in genes encoding the alpha3, alpha4, or alpha5 chains of type IV collagen, which form the collagenous network of mature glomerular basement membrane (GBM). In the absence of alpha3, alpha4, alpha5 (IV) collagen, alpha1, alpha2 (IV) collagen persists, which ordinarily is found only in GBM of developing kidney. In addition to dysregulation of collagen IV, Alport GBM contains aberrant laminins, which may contribute to the progressive GBM thickening and splitting, proteinuria, and renal failure seen in this disorder. This study sought to characterize further the laminin dysregulation in collagen alpha3(IV) knockout mice, a model of Alport disease. With the use of confocal microscopy, laminin alpha1 and alpha5 abundance was quantified, and it was found that they co-distributed in significantly large amounts in areas of GBM thickening. In addition, labeling of entire glomeruli for laminin alpha5 was significantly greater in Alport mice than in wild-type siblings. Reverse transcriptase-PCR from isolated glomeruli demonstrated significantly more laminin alpha5 mRNA in Alport mice than in wild-type controls, indicating upregulated transcription of Lama5. For testing glomerular barrier function, ferritin was injected into 2-wk-old Alport and control mice, and GBM was examined by electron microscopy. Highest ferritin levels were seen in Alport GBM thickenings beneath effaced podocyte foot processes, but morphologically normal GBM was significantly permeable as well. We concluded that (1) ultrastructurally normal Alport GBM residing beneath differentiated podocyte foot processes is inherently and abnormally permeable, and (2) upregulation of Lama5 transcription and concentration of laminin alpha1 and alpha5 within Alport GBM thickenings contribute to abnormal permeabilities.
Similar articles
-
Laminin-1 reexpression in Alport mouse glomerular basement membranes.Kidney Int. 2003 Mar;63(3):826-34. doi: 10.1046/j.1523-1755.2003.00800.x. Kidney Int. 2003. PMID: 12631063
-
Quantitative analysis of type IV collagen subchains in the glomerular basement membrane of patients with Alport syndrome with confocal microscopy.Nephrol Dial Transplant. 2006 Jul;21(7):1838-47. doi: 10.1093/ndt/gfl090. Epub 2006 Mar 30. Nephrol Dial Transplant. 2006. PMID: 16574687
-
Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome.Stem Cells. 2006 Nov;24(11):2448-55. doi: 10.1634/stemcells.2006-0201. Epub 2006 Jul 27. Stem Cells. 2006. PMID: 16873763
-
Molecular characterization of the target antigens of anti-glomerular basement membrane antibody disease.Springer Semin Immunopathol. 2003 May;24(4):345-61. doi: 10.1007/s00281-002-0103-1. Springer Semin Immunopathol. 2003. PMID: 12778332 Review.
-
Inherited diseases of the glomerular basement membrane.Nat Clin Pract Nephrol. 2008 Jan;4(1):24-37. doi: 10.1038/ncpneph0671. Nat Clin Pract Nephrol. 2008. PMID: 18094725 Review.
Cited by
-
Glomerular Basement Membrane Protein Expression and the Diagnosis and Prognosis of Autosomal Dominant Alport Syndrome.Kidney Med. 2019 Aug 20;1(6):391-396. doi: 10.1016/j.xkme.2019.06.007. eCollection 2019 Nov-Dec. Kidney Med. 2019. PMID: 32734219 Free PMC article.
-
The glomerular basement membrane as a barrier to albumin.Nat Rev Nephrol. 2013 Aug;9(8):470-7. doi: 10.1038/nrneph.2013.109. Epub 2013 Jun 18. Nat Rev Nephrol. 2013. PMID: 23774818 Free PMC article. Review.
-
An update on the pathomechanisms and future therapies of Alport syndrome.Pediatr Nephrol. 2013 Jul;28(7):1025-36. doi: 10.1007/s00467-012-2272-z. Epub 2012 Aug 18. Pediatr Nephrol. 2013. PMID: 22903660 Review.
-
Hanging on for the ride: adhesion to the extracellular matrix mediates cellular responses in skeletal muscle morphogenesis and disease.Dev Biol. 2015 May 1;401(1):75-91. doi: 10.1016/j.ydbio.2015.01.002. Epub 2015 Jan 12. Dev Biol. 2015. PMID: 25592225 Free PMC article. Review.
-
Progress in therapeutic targets on podocyte for Alport syndrome.J Transl Int Med. 2024 May 21;12(2):129-133. doi: 10.2478/jtim-2024-0005. eCollection 2024 Apr. J Transl Int Med. 2024. PMID: 38812923 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases